May 17, 2023Support Agreement • May 19th, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
The undersigned understands that Alimera Sciences, Inc., a Delaware corporation (“Company”), and certain investors, including the undersigned (the “Investors”), are entering into a Joinder and Amendment to Securities Purchase Agreement dated as of the date hereof (the “Amendment”), which amends that certain Securities Purchase Agreement dated as of March 24, 2023 (the “Securities Purchase Agreement”). All capitalized terms used in this letter agreement but not defined in this letter agreement shall have the meanings given such terms in the Securities Purchase Agreement, as amended. The undersigned is a stockholder of the Company and is entering into this letter agreement to induce the Company to enter into the Amendment and to consummate the transactions contemplated thereby.
JOINT FILING AGREEMENTJoint Filing Agreement • May 19th, 2023 • Velan Capital Investment Management LP • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
